398 related articles for article (PubMed ID: 33494751)
1. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
[TBL] [Abstract][Full Text] [Related]
2. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
[TBL] [Abstract][Full Text] [Related]
3. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
4. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Zhang DP; Xu L; Wang LF; Wang HJ; Jiang F
Cardiovasc Diabetol; 2020 Jan; 19(1):10. PubMed ID: 31969144
[TBL] [Abstract][Full Text] [Related]
5. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
6. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.
Chen J; Jiang C; Guo M; Zeng Y; Jiang Z; Zhang D; Tu M; Tan X; Yan P; Xu X; Long Y; Xu Y
Cardiovasc Diabetol; 2024 Jan; 23(1):2. PubMed ID: 38172861
[TBL] [Abstract][Full Text] [Related]
7. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study.
Gamaza-Chulián S; Díaz-Retamino E; González-Testón F; Gaitero JC; Castillo MJ; Alfaro R; Rodríguez E; González-Caballero E; Martín-Santana A
BMC Cardiovasc Disord; 2021 Sep; 21(1):456. PubMed ID: 34548011
[TBL] [Abstract][Full Text] [Related]
8. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
9. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
10. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
12. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
[TBL] [Abstract][Full Text] [Related]
13. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
14. The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.
Zhang Y; Yang D; Jia Q; Yan J; An F
Diabetes Obes Metab; 2024 Jun; 26(6):2401-2411. PubMed ID: 38528818
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
Mentz RJ; Brunton SA; Rangaswami J
Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
[TBL] [Abstract][Full Text] [Related]
16. Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.
Kang DH; Park SJ; Shin SH; Hwang IC; Yoon YE; Kim HK; Kim M; Kim MS; Yun SC; Song JM; Kang SM
Circulation; 2024 Jun; 149(24):1865-1874. PubMed ID: 38690659
[TBL] [Abstract][Full Text] [Related]
17. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
[TBL] [Abstract][Full Text] [Related]
18. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
19. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
Natali A; Nesti L; Tricò D; Ferrannini E
Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
[TBL] [Abstract][Full Text] [Related]
20. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
